Phase 4
Completed N=30
Spironolactone After Liver Transplant
Transplant, Liver
Source: ClinicalTrials.gov NCT02883400 ↗
Enrolled (actual)
30
Serious AEs
13.3%
Results posted
Jun 2021
Primary outcomePrimary: Glomerular Filtration Rate (GFR) — 69; 64 ml/min/1.73m^2 — p=0.0001
◆ Published Evidence
No publication linked
No peer-reviewed publication reporting this trial's results has been linked yet. This can indicate results are unpublished — a known publication-bias signal. We re-check periodically.
Summary
To study spironolactone to prevent calcineurin inhibitor (CNI) kidney injury.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Glomerular Filtration Rate (GFR) |
69; 64 | 0.0001 sig |
Eligibility Criteria
Inclusion Criteria
- liver transplant
Exclusion Criteria
- dual organ transplant
Data sourced from ClinicalTrials.gov (NCT02883400). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.